Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0992
Source ID: NCT00830037
Associated Drug: Iv Iron
Title: A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00830037/results
Conditions: Chronic Kidney Disease|Iron-deficiency Anemia
Interventions: DRUG: IV Iron|DRUG: Ferrous Sulfate
Outcome Measures: Primary: Mean Rate of Decline in mGFR in the Two Groups - Oral and IV Iron, Plasma clearance of iothalamate was measured by administering an IV bolus of 5 mL of iothalamate meglumine and sampling 2 mL of blood at 0, 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, and 300 min after injection. Iothalamate was measured by high-performance liquid chromatography. Plasma clearance was calculated using a two-pool model using validated pharmacokinetic software. The mean modeled iothalamate mGFR slope (e.g., change from baseline to 2 years) in each group (IV iron vs. oral iron) was then calculated after adjustment for baseline log urinary protein/creatinine ratio., Baseline, 2 years | Secondary: Proteinuria, Proteinuria was estimated using measurements of urinary protein and creatinine before iron administration at baseline and at periodic intervals thereafter. Mean change from baseline log urinary protein/creatinine ratio (g/g) is reported at 2 years., Baseline, 2 years
Sponsor/Collaborators: Sponsor: Indiana University | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 136
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2008-08
Completion Date:
Results First Posted: 2016-07-21
Last Update Posted: 2016-07-21
Locations: VA Medical Center, Indianapolis, Indiana, 46202, United States
URL: https://clinicaltrials.gov/show/NCT00830037